anti-Cytochrome P450, Family 46, Subfamily A, Polypeptide 1 (CYP46A1) Antibodies

Human Cytochrome P450, Family 46, Subfamily A, Polypeptide 1 (CYP46A1) interaction partners

1. Polymorphism within the CYP46A1 gene is a positive risk factor for type 2 diabetes mellitus.

2. the APOEepsilon4 alleles were significantly higher in patients with Alzheimer's disease (AD) and there was a potential synergistic interaction between the CYP46A1 C allele and APOEepsilon4 allele in AD.

3. Data suggest that CYP46A1, the enzyme responsible for the majority of cholesterol elimination from the brain, exhibits activation by neurotransmitters, L-glutamate, L-aspartate, gamma-aminobutyric acid, and acetylcholine; L-glutamate-induced CYP46A1 activation may be of physiological relevance.

4. CYP46A1 rs4900442 genetic polymorphism was associated with increased risk of Alzheimer disease in the Chinese population, but no evidences were detected in Caucasian population.

5. Findings of this study suggest that CYP46A1 gene and PPARgamma2 gene polymorphisms can be a predictive marker for early identification of population at risk of primary open angle glaucoma (POAG).

6. hippocampal CYP46A1 protein and 24S-hydroxycholesterol levels were reduced in a mouse model of Alzheimer's Disease-like Tau neuropathology

7. under conditions of membrane cholesterol reduction by increased CYP46A1 expression, neurons increase isoprenoid synthesis and sGTPase prenylation. This leads to a reduction in liver X receptor activity

8. Human CYP46A1 oxidizes 7-dehydrocholesterol to 24-hydroxy-7-dehydrocholesterol and 25-hydroxy-7-dehydrocholesterol.

9. While there were no differences in cognitive performance between participants with and those without metabolic syndrome, ApoE and CYP46 genotypes did correlate with mental manipulation scores.

10. results of meta-analysis suggested that CYP46A1 rs754203 is a minor risk factor for Alzheimer's disease

11. An meta-analysis has successfully proved that CC genotype of the CYP46A1 T/C polymorphism could increase the risk of Alzheimer's disease.

12. A meta-analysis indicates that the CYP46 gene SNP rs754203 is not significantly associated with sporadic Alzheimer's disease susceptibility in Chinese Han populations.

13. To identify the determinants of tight azole binding to CYP46A1.

14. analysis of binding of the cyano- and fluoro-containing drug bicalutamide to cytochrome P450 46A1

15. The intronic polymorphism in CYP46A1 is associated with Alzheimer disease in a Chinese Han population, and the CYP46A1 T allele might be a risk factor.

16. The rs754203 C allele in the CYP46A1 gene may confer a higher risk for exudative age-related macular degeneration in patients who carry no risk alleles in the CFH and LOC387715 genes.

17. Differentiated Ntera2/clone D1 (NT2) cells express the key genes involved in brain cholesterol homeostasis including CYP46A1.

18. There was no association between the CYP46 genotype and measures of cognitive event-related potentials.

19. Study of two independent Chinese data sets indicates individuals with CYP46A1 promoter bearing the CG haplotype are genetically more susceptible to Alzheimer's disease than those with TA haplotype.

20. The data of this study suggested that CYP46 T/C SNP modulates parahippocampal and hippocampal morphology in young subjects.

Mouse (Murine) Cytochrome P450, Family 46, Subfamily A, Polypeptide 1 (CYP46A1) interaction partners

1. Enhanced cholesterol turnover by activation of CYP46A1 represents disrupted brain cholesterol homeostasis early after neonatal hypoxia-ischemia

2. Oral administration of a small dose of the anti-HIV drug efavirenz to a mouse model of Alzheimer's disease ameliorated amyloid pathology in the brain and led to changes supporting therapeutic potential of cholesterol-metabolizing enzyme CYP46A1, its metabolite 24HC and 24HC-mediated liver X receptors transrepression of some of the inflammatory genes in astrocytes and microglia surrounding amyloid plaques.

3. The present study demonstrates the diverse potential effects of CYP46A1 deficiency on brain functions and identifies important proteins that could be affected by this deficiency

4. Increased expression of CYP46A1 in the striatum decreased neuronal atrophy in a Huntington's disease model.

5. under conditions of membrane cholesterol reduction by increased CYP46A1 expression, neurons increase isoprenoid synthesis and sGTPase prenylation. This leads to a reduction in liver X receptor activity

6. EFV enhanced CYP46A1 activity and cerebral cholesterol turnover in animals with no effect on the levels of brain cholesterol.

7. the CYP46 gene locus may predispose to Alzheimer's disease by increasing the 24S-hydroxycholesterol/cholesterol ratio in the brain.

8. constitutes a major tissue-specific pathway for cholesterol turnover in the brain

9. The expression of CYP46A1, as well as other cytochrome P450s involved in cholesterol homeostasis, are potently regulated by histone acetylation status.

Cow (Bovine) Cytochrome P450, Family 46, Subfamily A, Polypeptide 1 (CYP46A1) interaction partners

1. EFV enhanced CYP46A1 activity and cerebral cholesterol turnover in animals with no effect on the levels of brain cholesterol.

2. analysis of binding of the cyano- and fluoro-containing drug bicalutamide to cytochrome P450 46A1

3. Neural retina specifically expresses cholesterol-24S-hydroxylase, a metabolizing enzyme responsible for the removal of cholesterol in neurons. May be valuable gene candidate for retinal pathologies.